Krieg AM - Search Results

1

CpG DNA: trigger of sepsis, mediator of protection, or both?

Krieg AM. Krieg AM. Scand J Infect Dis. 2003;35(9):653-9. doi: 10.1080/00365540310015999. Scand J Infect Dis. 2003. PMID: 14620150 Review.

2

Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant.

Reeman S, Gates AJ, Pulford DJ, Krieg A, Ulaeto DO. Reeman S, et al. Viruses. 2017 Dec 9;9(12):378. doi: 10.3390/v9120378. Viruses. 2017. PMID: 29232844 Free PMC article.

3

Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, Broyer S, Couture L, Nakamura R, Dadwal S, Kelsey MI, Krieg AM, Diamond DJ, Zaia JA. La Rosa C, et al. Among authors: krieg am. J Infect Dis. 2012 Apr 15;205(8):1294-304. doi: 10.1093/infdis/jis107. Epub 2012 Mar 7. J Infect Dis. 2012. PMID: 22402037 Free PMC article. Clinical Trial.

4

Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, Davis HL, Schetter C, Krieg AM. Vollmer J, et al. Among authors: krieg am. Immunology. 2004 Oct;113(2):212-23. doi: 10.1111/j.1365-2567.2004.01962.x. Immunology. 2004. PMID: 15379982 Free PMC article.

5

Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer.

Lubaroff DM, Karan D, Andrews MP, Acosta A, Abouassaly C, Sharma M, Krieg AM. Lubaroff DM, et al. Among authors: krieg am. Vaccine. 2006 Aug 28;24(35-36):6155-62. doi: 10.1016/j.vaccine.2006.04.022. Epub 2006 May 3. Vaccine. 2006. PMID: 16876291

6

Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy.

Kline JN, Krieg AM. Kline JN, et al. Among authors: krieg am. Drug News Perspect. 2008 Oct;21(8):434-9. doi: 10.1358/dnp.2008.21.8.1272133. Drug News Perspect. 2008. PMID: 19034349 Review.

7

Oral pretreatment of mice with CpG DNA reduces susceptibility to oral or intraperitoneal challenge with virulent Listeria monocytogenes.

Ray NB, Krieg AM. Ray NB, et al. Among authors: krieg am. Infect Immun. 2003 Aug;71(8):4398-404. doi: 10.1128/IAI.71.8.4398-4404.2003. Infect Immun. 2003. PMID: 12874318 Free PMC article.

8

Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself.

Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R. Li J, et al. Among authors: krieg am. J Immunol. 2007 Aug 15;179(4):2493-500. doi: 10.4049/jimmunol.179.4.2493. J Immunol. 2007. PMID: 17675511

9

CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection.

Deng JC, Moore TA, Newstead MW, Zeng X, Krieg AM, Standiford TJ. Deng JC, et al. Among authors: krieg am. J Immunol. 2004 Oct 15;173(8):5148-55. doi: 10.4049/jimmunol.173.8.5148. J Immunol. 2004. PMID: 15470059 Free PMC article.

10

P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides.

Krieg AM, Guga P, Stec W. Krieg AM, et al. Oligonucleotides. 2003;13(6):491-9. doi: 10.1089/154545703322860807. Oligonucleotides. 2003. PMID: 15025915

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results